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(57) ABSTRACT 
Provided are methods for screening for drugs effective for 
treating ?brotic conditions. One screening method comprises 
exposing a cell to a test compound, monitoring the effect of 
the test compound on the amount or form of a cell molecule, 
comparing the amount or form of the cell molecule With the 
result obtained by treatment of the cell With an anti-?brotic - 
effective amount of a Withanolide compound, and selecting a 
drug effective for treating a ?brotic disease based on the 
ability of the test compound to provide the effect obtained by 
the Withanolide compound on the cell molecule. Also pro 
vided is a method of treating a ?brotic disease comprising 
administering an anti-?brotic effective amount of a Withano 
lide compound to a mammal in need of treatment for ?brosis. 
7 Claims, No Drawings 
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WITHANOLIDE COMPOUNDS AS 
INHIBITORS OF FIBROSIS AND 
IDENTIFICATION OF MOLECULAR 
TARGETS FOR ANTI-FIBROTIC DRUG 
DEVELOPMENT 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to US. Provisional Appli 
cation No. 60/781,973, ?led Mar. 13, 2006, Which is incor 
porated herein in its entirety. 
FIELD OF THE INVENTION 
The present invention relates to methods of screening com 
pounds for treating ?brosis and to methods for treating ?bro 
sis. 
DESCRIPTION OF THE RELATED ART 
Fibrosis is a deviant process of tissue repair. It is a serious 
complication after major surgical procedures and organ trans 
plants, and can also occur during cancerous groWth, 
endometriosis, alcohol-related liver damage, cardiovascular 
disease, retinal detachment, and other disorders. Thus, ?bro 
genic complications contribute to the pathogenesis of many 
common and devastating diseases and yet there is no effective 
treatment for this chronic problem. Hence, an unaddressed 
need exists in the industry to address the aforementioned 
de?ciencies and inadequacies. 
SUMMARY OF THE INVENTION 
In one embodiment, the invention provides a method of 
screening for a drug effective for treating a ?brotic disease. 
The method comprises exposing a cell to a test compound, 
monitoring the effect of the test compound on the amount or 
form of a cell molecule, comparing the amount or form of the 
cell molecule With the result obtained by treatment of the cell 
With an anti-?brotic-effective amount of a Withanolide com 
pound, and selecting a drug effective for treating a ?brotic 
disease based on the ability of the test compound to provide 
the effect obtained by the Withanolide compound on the cell 
molecule. 
In another embodiment, the invention provides a method of 
screening for a drug effective for treating a ?brotic disease. 
The method comprising exposing a cell to a test compound, 
monitoring the effect of the test compound on the intracellular 
activity of the ubiquitin proteasome pathWay (U PP), compar 
ing the intracellular activity of the UPP With the result 
obtained by treatment of the cell With an anti-?brotic-effec 
tive amount of a Withanolide compound, and selecting a drug 
effective for treating a ?brotic disease based on the ability of 
the test compound to provide the effect obtained by the Witha 
nolide compound on the UPP. 
In yet another embodiment, the invention provides a 
method of treating a ?brotic disease comprising administer 
ing an anti-?brotic effective amount of a Withanolide com 
pound to a mammal in need of treatment for ?brosis. Also 
provided is a composition for the treatment of ?brosis com 
prising a Withanolide compound Which inhibits intracellular 
ubiquitination of transketolase. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The invention relates generally to methods for treating 
?brotic conditions and to procedures for identifying drugs for 












Any ?brotic condition can be the subject of the invention, 
such as the ?brosis that is associated With organ failure in a 
variety of chronic diseases affecting the lungs, kidney, eyes, 
heart, liver and skin. Such ?brotic conditions include diabetic 
nephropathy, glomerulosclerosis, IgA nephropathy, diabetic 
retinopathy, advanced macular degeneration, liver cirrhosis 
and biliary atresia, congestive heart failure, endomyocardial 
?brosis, idiopathic myocardiopathy, lung ?brosis, diffuse 
parenchymal lung disease, mediastinal ?brosis, progressive 
massive ?brosis, ?brosis of the lungs associated With tuber 
culosis, scleroderma, ?brosis associated With cancerous 
groWth, endometriosis, ?brosis associated With surgery, alco 
hol-related liver damage, cardiovascular disease, and retinal 
detachment. 
The present inventors have discovered that in?ammation 
and ?brosis are associated With activation of the in?amma 
tory transcription factor NF-kappa-B, a key mediator of 
cytokine gene activation and immune regulation. Activation 
of NF-kappa-B occurs in coordination With increases in the 
biochemical activities of the ubiquitin proteasome pathWay 
(U PP), the principal machinery for intracellular protein deg 
radation. Inhibiting the UPP via an appropriate inhibitor is 
used according to the present invention to identify com 
pounds Which are effective for treating ?brosis. Inhibition of 
the UPP is also associated With a reduction in the level of 
ubiquitinated transketolase in the cell. In another embodi 
ment, the effect of a test compound on a cell molecule is 
compared With the effect of a Withanolide compound to deter 
mine Whether the test compound is effective for treating a 
?brotic disease. Also described is a method of treating ?brosis 
via administration of a UPP-inhibitory compound. In one 
embodiment, a ?brotic condition is treated by administration 
of a Withanolide compound. 
The methods of the present invention can be used With any 
mammalian species, including human, monkey, coW, sheep, 
pig, goat, horse, mouse, rat, dog, cat, rabbit, guinea pig, 
hamster and horse. Humans are preferred. 
In performing screening procedures for identifying UPP 
inhibitory compounds, any mammalian cell, tissue or organ 
can be used according to the present invention. Such screen 
ing procedures can be performed in vitro or in vivo. For 
example, cells in culture can be exposed to a test compound 
for evaluation as to Whether the test compound possesses 
UPP-inhibitor activity. In another embodiment, test com 
pound canbe administered to a subject, and then cells, a tissue 
or an organ can be removed from the subject and then be 
evaluated as to Whether the test compound possesses UPP 
inhibitory activity. 
Appropriate mammalian cells for use in the screening pro 
cedures of the invention include, by Way of example, neural 
cells, epithelial cells, epidermal cells, keratinocytes, hemato 
poietic cells, melanocytes, chondrocytes, lymphocytes (B 
and T lymphocytes), erythrocytes, macrophages, monocytes, 
mononuclear cells, ?broblasts, hepatocytes, cardiac muscle 
cells or other muscle cells, or a corneal cell, choroidal cell or 
any other cell of the eye, etc. Cells Which can be used include 
all somatic or germ cells. Moreover, any mammalian organ or 
cells from any organ may be used, e. g., eye, brain, skin, lung, 
pancreas, liver, stomach, intestine, esophagus, spleen, thy 
mus, thyroid gland, salivary gland, bone, heart, skeletal 
muscle, reproductive organs, bladder, kidney, urethra and 
other urinary organs, etc. 
Withanolide compounds are inhibitors of the UPP. Thus, in 
evaluating Whether a test compound possesses anti-?brotic 
activity, the effect of a test compound can be compared With 
the effect of a Withanolide compound. 
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Withanolides Were ?rst characterized as bioactive sub 
stances present in the plant Wilhania somnifera. Chemically, 
Withanolides are steroidal lactones. Exemplary Withanolides 
Which possess UPP-inhibitory activity include Withaferin A, 
Withanolide D and ixocarpalactone A. In general, Withano 
lides Which possess UPP-inhibitory activity have a steroid 
structure With an alpha, beta-unsaturated ketone in theA ring, 
a 4-beta-hydroxy substituent, a 5,6 beta-epoxide, and a 5- or 
6-member lactone substituent attached to the D ring. 
The present invention also provides a method of treating a 
?brotic disease, comprising administering an anti-?brotic 
effective amount of a Withanolide compound to a mammal in 
need of treatment for ?brosis. Such ?brotic diseases include 
any of the conditions enumerated above. 
According to the method of the invention, one or more 
Withanolide compounds can be administered to the host by an 
appropriate route, either alone or in combination With another 
drug. An effective amount of a Withanolide compound is 
administered. An effective amount is an amount suf?cient to 
achieve the desired therapeutic effect, under the conditions of 
administration, such as an amount su?icient for inhibition of 
the UPP, and thereby effectively treat ?brosis. 
A variety of routes of administration are possible includ 
ing, but not necessarily limited to oral, dietary, topical, 
parenteral (e.g., intravenous, intraarterial, intramuscular, sub 
cutaneous injection), inhalation (e.g., intrabronchial, intrana 
sal or oral inhalation, intranasal drops), and intraocular inj ec 
tion routes of administration, depending on the disease or 
condition to be treated. Intraocular injection routes include 
periocular (subconjunctival/transscleral), intravitreous, sub 
retinal and intracameral modes of injection. 
Formulation of a Withanolide compound to be adminis 
tered Will vary according to the route of administration 
selected (e.g., solution, emulsion, capsule). An appropriate 
composition comprising the Withanolide compound to be 
administered can be prepared in a physiologically acceptable 
vehicle or carrier. The Withanolide compound compositions 
of the invention include sustained release formulations. For 
solutions or emulsions, suitable carriers include, for example, 
aqueous or alcoholic/aqueous solutions, emulsions or sus 
pensions, including saline and buffered media. Parenteral 
vehicles can include sodium chloride solution, Ringer’s dex 
trose, dextrose and sodium chloride, lactated Ringer’s or 
?xed oils. Intravenous vehicles can include various additives, 
preservatives, or ?uid, nutrient or electrolyte replenishers 
(See, generally, Remington’s Pharmaceutical Science, 16th 
Edition, Mack, Ed. 1980). For inhalation, the Withanolide 
compound is solubiliZed and loaded into a suitable dispenser 
for administration (e.g., an atomiZer, nebuliZer or pressurized 
aerosol dispenser). 
Studies of Fibrosis in the Eye 
The eye is among the organs in Which ?brosis can occur. 
Tissue repair in the cornea usually occurs through a regen 
erative mechanism Which helps the cornea regain its optical 
function. This property has made corneal transplant surgery 
and vision corrective surgical procedures a great success. 
HoWever, alkali burn injuries, severe mechanical trauma and 
infectious agents can cause corneal ?brosis, and it is this 
impaired form of tissue repair that results in blindness. Since 
the cornea can feature a regenerative or ?brotic phenotype 
based on the type of injury, this tissue serves as an excellent 
model to study the molecular mechanisms of ?brosis. 
Corneal Wound healing is a tightly coordinated process that 
must regenerate the biological and optical functions of this 
refractive tissue. This process is coordinated through auto 
crine and paracrine interactions of groWth factors, cytokines 












cells and lacrimal gland cells. It has been suggested that the 
in?ammation transcription factor NF-kappaB plays a role in 
tissue repair by controlling cytokine autocrine loops, i.e., 
IL-1-alpha expression. IL-1-alpha is a potent stimulator of 
collagenase gene expression, and its overproduction is 
observed in trauma situations such as alkali and thermal burn, 
Which can cause severe tissue maceration due to uncontrolled 
production of stromal collagenase. Thus silencing of NF 
kappaB may be a requirement for maintenance of corneal 
clarity, immune deviation and avascularity during tissue 
repair. HoWever, What signals overcome the competence to 
activate NF-kappaB When corneal tissue is injured has 
remained elusive. 
Recently, using the keratocyte and ?broblast culture model 
as representative of regenerative and ?brogenic repair mecha 
nisms, respectively, Stramer et at (Invest. Ophthalmol. I/zs. 
Sczl, 42(8):1698-1706, 2001) shoWed that transition to the 
repair ?broblast phenotype during the 3 days after initial 
plating is coincident With progressive induction of the ubiq 
uitin proteasome pathWay (UPP). Levels of free ubiquitin 
(Ub), Ub-conjugated proteins, ubiquinylating enZymes E1 
and E2-25K, and 26S proteasome Were increased 2-5-fold in 
stromal cells as they transitioned from the keratocyte pheno 
type into repair ?broblast phenotype. These increases Were 
associated With enhanced (>10-fold) capacity for Ub-depen 
dent proteolysis. The levels of native I-kappa-B-alpha, but not 
that of its phosphorylated form, Was elevated in activated 
?broblasts compared to keratocytes, suggesting that the con 
stitutive activation of NF-kappaB promotes native I-kappa 
B-alpha synthesis but, due to increased proteasome activity, 
the inhibitory form (phosphorylated I-kappa-B-alpha) is rap 
idly degraded. Both freshly isolated and activated ?broblasts 
degraded I-kappa-B-alpha in response to IL-1-alpha; yet, 
only activated ?broblasts maintained autocrine IL-1-alpha 
expression after 24 hours. These authors conclude that coor 
dinate induction of the UPP during ?broblast activation that 
causes activated I-kappa-B-alpha to be rapidly degraded may 
drive the autocrine IL-1-alpha loop, perpetuating a chronic 
state of in?ammation. Since the UPP regulates NF-kappaB 
activation through its orchestrated degradation of I-kappa-B 
alpha, the cytoplasmic inhibitor of NF -kappaB, targeting the 
UPP may be a novel means of doWnregulating corneal ?bro 
sis. The UPP has become the center of great attention because 
of its critical role in in?ammation and ?brovascular groWth, 
and as an important source of multiple sites for pharmaco 
logical targeting. 
The abundant corneal protein tissue transketolase (TKT) is 
believed to play an important role in corneal homeostasis. 
TKT is also a target of the UPP and its reduced expression is 
believed to contribute to corneal ?brosis. In the present inven 
tion, targeting the UPP in injured tissue can redirect the 
?brotic repair process to acquire regenerative healing. Witha 
nolides and related compounds, such as Withaferin A, Witha 
nolide D and ixocarpalactone, are small molecule inhibitors 
that have potent UPP-targeting activity. Exposure to Witha 
ferinA causes potent doWnregulation of UPP functions in the 
alkali burn injury model of corneal angio?brotic disease. 
There is also a reduction in the levels of ubiquitinated tran 
sketolase (TKT), an abundant corneal protein implicated in 
?brogenesis. 
EXAMPLE 1 
The corneas of C57BL6 mice under anesthesia Were 
injured by application of 0.1 N sodium hydroxide and subse 
quently the epithelial cell layer from the cornea and limbus 
Was removed by scraping. WithaferinA (WA) (2.5 mg/kg/d; 4 
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mice) or vehicle (DMSO; 4 mice) Was provided daily there 
after by i.p. injection for 6 d. Digital images of the corneas 
Were obtained to assess the extent of tissue pathology. 
Vehicle-treated mice display profound corneal opacity and 
abundant groWth of neW blood vessels, Whereas in 
WA-treated mice both the corneal opacity and neovascular 
iZation are dramatically reduced. These compelling results 
invoke the query Whether WA targets the UPP in vivo. Mice (4 
per group) Were injured and treated for the ?rst 4 days With a 
different dose of WA or vehicle daily by i.p. injection. On day 
7, mice Were sacri?ced and corneal buttons Were isolated 
from injured healing corneas; equal amounts of protein from 
each group Were analyzed by Western blotting. Uninjured 
felloW eyes from vehicle-treated mice served as controls. 
We discovered that WA dose-dependently inhibits corneal 
expression of native l-kappa-B-alpha, Whereas expression of 
native l-kappa-B-alpha in vehicle-treated mice Was highly 
elevated compared to uninjured corneas. We also assessed the 
expression levels of HO-l, since its expression is upregulated 
by angiogenic inducers during response to in?ammation. WA 
potently doWnregulated HO-l expression to almost undetect 
able levels as found in uninjured corneas. These ?ndings that 
inhibition of l-kappa-B-alpha and HO-l expression by WA 
hence corroborate the potent pharmacological activity of WA 
an inhibitor of angio?brosis. 
EXAMPLE 2 
WA Reduces Injury-Induced Expression of 
Ubiguitinated Transketolase in the Cornea 
During tissue injury, TKT expression is doWnregulated in a 
UPP-dependent manner as the tissue progresses into ?brosis. 
To investigate the levels and timing of expression of TKT We 
performed time-course experiments using the angioin?am 
mation corneal model of tissue repair. Groups of mice (n:0.3/ 
group) Were injured and treated every day With vehicle (Veh), 
2.5 mg/kg/ d WA or 2.0 mg/kg/d epoxomicin (20S proteasome 
inhibitor) and sacri?ced on day 4 and 6 post-in?ammation. In 
a similar experiment, mice Were treated every day With 
vehicle or 2.5 mg/kg/d WA and sacri?ced on days 3 and 5 
post-injury. Equal amounts of protein from pooled samples of 
each group Were subjected to immunoblotting or Coomassie 
blue staining after fractionation on 4-20% gradient polyacry 
lamide gels (BioRad). 
We observed that a 70 kDa ubiquitinated protein Was abun 
dantly expressed in vehicle-treated mouse corneas compared 
to corneas from WA-treated mice. Coomassie blue staining, 
hoWever, revealed that the levels of this protein Were not 
signi?cantly altered betWeen uninjured, vehicle and 
WA-treated samples at the 3- and 5-day time-points, or at the 
4- and 6-day time-points examined (data not shoWn). The 
Western blots of the corneal samples Were re-probed With an 
anti-mouse TKT antibody. We discovered that the uninjured 
corneas expressed high levels of TKT as anticipated, but 
surprisingly TKT from injured corneas did not bind this anti 
body. Because of the strong Ub-immunoreactivity of TKT in 
injured corneas, We speculate that this protein’s N-terminal 
antigenic site is being masked by ubiquitination in the injury 
related samples (the TKT antibody reacts With the N-terminal 
20-amino acid portion of native TKT). Our ?ndings are con 












in ?brotic cells. We believe that TKT is conjugated With 
mono-ubiquitin species, rather than polyubiquitin species, 
because the ubiquitin immunoreactivity of the 70 kDa protein 
does not smear all the Way up to the top of the gel. 
Exposure of blots to X-ray ?lm for slightly longer periods 
of time (30-40 seconds instead of 5 minutes) revealed the 
presence of the TKT in WA- and epoxomicin-treated corneas, 
but not in vehicle-treated mouse corneas. To investigate the 
localization of TKT, immunohistochemical analysis of 
mouse eyes Was conducted. TKT expression is localiZed to 
the epithelium of uninjured mouse eyes, Whereas TKT 
expression in corneas of 4 d vehicle-treated mice is almost 
undetectable. Staining in corneas of WA-treated mice Was 
present, although at levels loWer than that of uninjured cor 
nea, With staining being predominantly in the epithelium, and 
very little in the stroma. 
This data is consistent With the general idea that ubiquiti 
nated proteins are generated in the corneal epithelium upon 
alkali burn injury as a result of oxidative damage, and removal 
of these damaged proteins is enabled by upregulation of the 
UPP. The persistent high amount of UbTKT in injured cor 
neas suggests that this protein is being retained in a posttrans 
lationally-modi?ed state. 
The prevailing hypothesis is that TKT plays a role in sup 
porting regenerative healing and response to environment 
stress. Our ?nding that uninjured mouse corneas also express 
UbTKT, although at loW levels, indicates that this variant is 
physiologically removed by the UPP, and that overexpres sion 
during severe tissue in?ammation promotes ?brosis. Hence, 
TKT is a neW molecular target for anti-?brosis drug develop 
ment. Moreover, WithaferinA and related Withanolides can be 
used to treat ?brotic conditions 
EXAMPLE 3 
Anti-Fibrogenic in vivo Activity of Withaferin A 
Under full anesthesia and application of topical ocular 
anesthetic solution, a 1-mm full-thickness button of central 
corneal tissue, including all three layers4epithelium, stroma 
and endotheliumiis ablated and the area is carefully scored 
by insertion and removal of a 26-gauge needle into the central 
cornea employing the use of a dissecting microscope. The 
full-thickness tissue button that is demarcated by the needle 
insertion is removed With microdissecting scissors. After 
approximately 15 minutes, a ?brin clot forms in this space, 
enabling the anterior chamber to reform. The cornea is cov 
eted With erythromycin and tobramycin ophthalmic ointment 
to prevent infections. Atropine is administered once daily for 
tWo days. The corneal tissue is harvested after 2, 5 and 8 days. 
In the ?rst experiment, the dose-response of corneal ?bro 
genesis to the inhibitory activity of WA in C57 BL/6J mice is 
determined. The drug is freshly diluted in 1:1 salinezDMSO 
and delivered by i.p. injection. Vehicle and WA at doses of 0.5, 
2.0, 5 .0 and 12.0 mg/kg/d are administered for 7 or 14 days (4 
mice/group/time point). A second experiment is terminated 
on days 3, 7, 10 and 14 (6 mice/group/time point) and 
employs an effective WA dose determined from experiment 1 , 
as Well as vehicle controls. 
Mice are visually scored for corneal opacity on days 7 and 
14 by employing an investigator masked to the identity of the 
treatment groups. Digital photographic images of corneas are 
also collected. These visual scores are corroborated by immu 
nohistological and Western blot analyses of mouse corneas 
after 7 days (for 3- and 7-day treatment) and 14 days (for 10 
and 14-day treatment). Three mouse corneas are employed 
for Western blots and three for sectioning. The immunohisto 
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logical analysis includes hematoxylin-eosin staining, alpha 
smooth muscle actin (marker of repair ?broblast-myo?bro 
blasts), phalloidin (?lamentous actin stress ?bers), TGF 
beta2 (myo?broblast-differentiation inducer), Mac-l 
staining (marker of monocytes and PMNs), HO-l, l-kappa 
B-alpha and ubiquitin using frozen sections. For Western 
blotting, HO-l, l-kappa-B-alpha, ubiquitin, TKT, alpha 
smooth muscle (sm) actin and TGF-beta2 expression are ana 
lyZed. 
All references cited in this disclosure are incorporated by 
reference to the same extent as if each reference had been 
incorporated by reference in its entirety individually. 
While the invention has been described in detail and With 
reference to speci?c embodiments thereof, it Will be apparent 
to one skilled in the art that various variations and modi?ca 
tions can be made therein Without departing from the sprit and 
scope thereof. All such variations and modi?cations are 
intended to be included Within the scope of this disclosure and 
the present invention and protected by the folloWing claims. 
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We claim: 
1. A method of treating a ?brotic disease in a mammal 
comprising administering an anti-?brotic effective amount of 
a Withanolide compound to a mammal in need of treatment 
for ?brosis of the eye Wherein the anti-?brotic effective 
amount is 0.5 to 12 mg/kg/day. 
2. The method of claim 1 Wherein the Withanolide com 
pound is Withthaferin A. 
3. The method of claim 1 Wherein the Withanolide com 
pound is Withthanolide D. 
4. The method of claim 1 Wherein the Withanolide com 
pound is ixocarpalactone A. 
5. The method of claim 1 Wherein the Withanolide com 
pound is orally administered to the mammal. 
6. The method of claim 1 Wherein the Withanolide com 
pound is intravenously administered to the mammal. 
7. The method of claim 1 Wherein the Withanolide com 
pound is intraocularly injected into the mammal. 
* * * * * 
